ライフサイエンスコーパス: discontinue

1 ion phase and 50.2% for patients who did not discontinue.

2 12 CLIPPERS cases when corticosteroids were discontinued.

3 ons in malaria can be sustained after IRS is discontinued.

4 nsitization is sustained after omalizumab is discontinued.

5 recur in the same locations when therapy is discontinued.

6 n-replicative state and activate when ART is discontinued.

7 t none have been approved and many have been discontinued.

8 r/20% O2 had blackened and the treatment was discontinued.

9 n control after overminus treatment has been discontinued.

10 anking period, all antiarrhythmic drugs were discontinued.

11 ligible shortly after randomization and were discontinued.

12 sustained 6 months after the incentives were discontinued.

13 month follow-up period, the intervention was discontinued.

14 drawal signs or symptoms when suvorexant was discontinued.

15 rane is complete 25 min after stimulation is discontinued.

16 enced a rejection episode when steroids were discontinued.

17 munotherapy might persist after treatment is discontinued.

18 ffects show extinction when reinforcement is discontinued.

19 not identified; all normalized when X-82 was discontinued.

20 atients receiving concomitant ITP medication discontinued 1 or more medication.

21 tudy prospectively enrolled CHB patients who discontinued 3 year-NA treatment.

22 PrEP was discontinued; 3 weeks later HIV RNA was detected in plas

23 Moreover, when cocaine use was discontinued 45 minutes later, dendritic spine morpholog

24 Although many people who discontinue a statin reinitiate treatment, statin persis

25 more, some patients may have had PPI therapy discontinued abruptly or inappropriately due to safety c

26 14), empirical antibiotic therapy was set to discontinue after 48 h in the electronic medical record

27 ver progressed on therapy, but treatment was discontinued after 10.3 months as a result of depressed

28 for all three patients, and antibiotics were discontinued after 2 days in the second and third patien

29 In 1 patient, OAC was discontinued after 40 days because of mechanical fall wi

30 historically high transmission where IRS was discontinued after a 4-year period followed by universal

31 or alone as protease inhibitor monotherapy (discontinued after week 96).

32 a period, with relief of symptoms, and then discontinued, after which relapse may occur.

33 Patients discontinued all lipid-lowering treatment except ezetimi

34 One patient (1%) with genotype 1a infection discontinued all study drugs due to an adverse event (ir

35 Twenty-one percent of patients (n = 12) discontinued all study therapy as a result of treatment-

36 five (5%) patients, and three (3%) patients discontinued all study treatment due to adverse events.

37 tients in the rilotumumab group subsequently discontinued all study treatment.

38 gent cocaine access, after which cocaine was discontinued and unreinforced lever pressing ensued.

39 The number discontinuing and the time to discontinuation did not di

40 The number discontinuing and the time to discontinuation did not di

41 Omalizumab was then discontinued, and subjects continued on 2000 mg of peanu

42 At month 28, omalizumab was discontinued, and subjects passing an oral food challeng

43 otics used in this context can be reduced or discontinued, and this has been a major focus of recent

44 To investigate the proportion of patients discontinuing anticoagulation treatment after PVI in ass

45 erved per year in 1 of every 74 patients who discontinue aspirin.

46 Patients who discontinued aspirin had a higher rate of cardiovascular

47 ipants eligible for this analysis, 724 (17%) discontinued assigned treatment within the first year of

48 g patients in whom antiplatelet drug use was discontinued at least 2 days before surgery, the inciden

49 All other therapy for malignancy was discontinued at least 4 weeks before CD30.CAR-T infusion

50 uggest that neuromuscular-blocking agents be discontinued at the end of life or when life support is

51 is (AST) have been noted when bivalirudin is discontinued at the end of the procedure, which is perha

52 ase and 10.8 months for patients who did not discontinue because of AEs ( P = .97).

53 = 176) at any time and in those who did not discontinue because of AEs (n = 231).

54 tion phase (n = 96) and in those who did not discontinue because of AEs (n = 233).

55 ng the induction phase and those who did not discontinue because of AEs.

56 plus emtricitabine and tenofovir alafenamide discontinued because of a drug-related adverse event (ur

57 Six patients (12%) discontinued because of a treatment-related AE.

58 (5%) of 115 patients in the ceritinib group discontinued because of adverse events compared with eig

59 19 women in the protease inhibitor group discontinued because of adverse events compared with fiv

60 Treatment was discontinued because of adverse events in 11 patients (2

61 11 (8%) patients in the atezolizumab group discontinued because of adverse events versus 30 (22%) p

62 Safety was assessed in treated patients who discontinued because of AEs (n = 176) at any time and in

63 sessed in all randomly assigned patients who discontinued because of AEs during the induction phase (

64 ive response rate was 58.3% for patients who discontinued because of AEs during the induction phase a

65 and had one or more post-baseline scans, or discontinued because of progressive disease or treatment

66 Two (3%) of 78 patients discontinued because of treatment-related adverse events

67 who had a Marsh score of greater than 1 were discontinued before dosing.

68 ter the screening oral gluten challenge were discontinued before dosing.

69 rexed, 73 [63%] to docetaxel, and three [3%] discontinued before receiving treatment).

70 cluded in the safety population (one patient discontinued before study drug intake).

71 gical implantation except in one patient who discontinued before the safety assessment.

72 in 22 (14%) patients, including 17 (11%) who discontinued both treatments for the same event and five

73 Pembrolizumab was discontinued by 91 patients (86.7%), including 67 (63.8%

74 e positive symptoms than for individuals who discontinue cannabis use and those who are non-users.

75 s known about the effect of continued versus discontinued cannabis use after the onset of psychosis.

76 e later cohort appeared to be more likely to discontinue care early, and this outcome appeared to be

77 ter cohort were significantly more likely to discontinue care in <16 weeks (19.8% versus 15.8%, p = 0

78 Patients who discontinued chemotherapy because of progressive disease

79 For the 3 discontinued cholesterol ester transfer protein inhibito

80 early: OR = 0.58, 95% CI: 0.39, 0.85) versus discontinued communication.

81 We discontinued contact precautions for patients with CDI,

82 ks were recorded over a 10-year period after discontinuing contact precautions for patients with CDI

83 Women discontinuing contraception provided daily first-morning

84 0.12 mg/kg per day at week 49; 5 responders discontinued corticosteroids.

85 CGM plus CSII group who completed the trial discontinued CSII.

86 outcomes between those who continued (CC) or discontinued (DC) cannabis use or were non-users (NC).

87 84%) of 2990 adults in incident ESKD cohorts discontinued dialysis compared with 64 (5%) of 1364 adul

88 Patients who discontinued double-blind treatment after at least 2 wee

89 Treatment was discontinued due to adverse events in three (3%) of 103

90 ients receiving adalimumab plus methotrexate discontinued due to adverse events.

91 ) in the tenofovir disoproxil fumarate group discontinued due to adverse events.

92 atin treatment group, one additional patient discontinued due to an adverse event (prostate cancer th

93 or the treatment of OAB, but development was discontinued due to unacceptable structure-based toxicit

94 However, their use was discontinued due to widespread drug resistance.

95 nia (21 [22%] of 97), with 18 (19%) patients discontinuing due to adverse events.

96 The study was discontinued early because of slow accrual after the enr

97 Dialysis was discontinued early in 9 of 41 patients in the PD group f

98 k frequency was 99.8% under progestins after discontinuing eOC (16 women), 93.8% under tranexamic aci

99 Three patients discontinued everolimus early.

100 rsonal safety and control over continuing or discontinuing exposure to artworks, thereby preventing n

101 verse events was more common among those who discontinued first-line treatment for this reason.

102 mice, or when treatment with the protein was discontinued, folliculogenesis resumed, suggesting rever

103 ng the study drug, and 27.4% of the patients discontinued follow-up.

104 1 inappropriate medication was successfully discontinued for 91 (39.1%) residents in the interventio

105 T-DM1 was discontinued for disease progression in 84% of patients

106 Immunosuppression can be discontinued from selected and stable patients after liv

107 articipants in the 200 mg ebselen group were discontinued from the study before the calibrated sound

108 Fifty-one patients (11.9%) discontinued from the study during the double-blind phas

109 At this cutoff date, all patients had been discontinued from treatment but 54 patients were continu

110 Eighty participants continued HA use and 14 discontinued HA use at the time of the questionnaire.

111 Those who discontinued HA use found either that using the HA did n

112 her risk of stroke if warfarin treatment was discontinued (hazard ratio, 4.6; 95% CI, 1.2-17.2; P = .

113 Five (16%) patients discontinued ibrutinib: three due to progression and two

114 th patients and consider how opioids will be discontinued if benefits do not outweigh risks.

115 According to local protocol, bleomycin was discontinued if hemoglobin-corrected DLCO (DLCOc) decrea

116 ican College of Radiology recommendations to discontinue imaging follow-up after 1 year of stability

117 The patient was able to discontinue immunosuppression and exogenous immunoglobul

118 e the most to gain and the most to lose from discontinuing immunosuppression (IS).

119 iated with a decreased risk of relapse after discontinuing immunosuppression.

120 Ceftolozane-tazobactam was discontinued in 1 patient (rash).

121 Patients and Methods IM was prospectively discontinued in 100 patients with CML with UMRD sustaine

122 Steroids were discontinued in 277 eyes (no steroid group) and continue

123 Treatment was discontinued in 54 (44%) patients, primarily due to prog

124 ed those drugs, and the use of the drugs was discontinued in 6 (33.3%) patients with negative scan re

125 Treatment with anti-PD-1 antibodies was discontinued in 7 patients.

126 complete remission, imatinib was tapered and discontinued in 8 FP and 1 MHES subjects.

127 found that antipsychotics can be reduced or discontinued in a substantial proportion of adults who u

128 IM1 study demonstrates that IM can safely be discontinued in patients with a sustained deep molecular

129 Purpose Imatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia (

130 ls, which persisted even after ibrutinib was discontinued, in 1 case even after 26 months.

131 The 3MR is effective in discontinuing inappropriate medication use in frail nurs

132 Other practices should be discontinued, including the use of levels of evidence an

133 Rs for VTE/IS among warfarin-treated persons discontinuing individual antihyperlipidemics.

134 the Rd group; 55 (23%) and 22 (10%) patients discontinued induction treatment because of adverse even

135 -LXA4 initiates the resolving phase early to discontinue inflammation post-MI, thereby reducing LV dy

136 Patients with MS who discontinued injectable DMT after a long period of relap

137 ed, exercise group-related AEs (n=2) did not discontinue intervention.

138 Three of nine subjects were able to discontinue intravenous immunoglobulin replacement thera

139 atments for the same event and five (3%) who discontinued ipilimumab for one event and later disconti

140 12 (8%) patients discontinued ipilimumab only and 14 (9%) discontinued pe

141 Bristol-Myers Squibb has discontinued its involvement in the development of BMS-9

142 uing ticagrelor up to the time of surgery or discontinuing its use less than 2 days before surgery wa

143 on for KI discontinuation, that patients who discontinue KI due to toxicity can respond to an alterna

144 h CLL (ibrutinib = 143; idelalisib = 35) who discontinued KI therapy.

145 Seven patients (2%) discontinued ledipasvir-sofosbuvir prematurely due to ad

146 in a substantial proportion of patients who discontinue long-term NA therapy; on-therapy VR > 24 mon

147 Expert guidelines recommend reducing or discontinuing long-term opioid therapy (LTOT) when risks

148 the effectiveness of strategies to reduce or discontinue LTOT and patient outcomes after dose reducti

149 interventions may be effective to reduce or discontinue LTOT and that pain, function, and quality of

150 However, when contingency management is discontinued, most addicts relapse to drug use.

151 determine the best methods for sequencing or discontinuing MS therapies.

152 al and clinical relapses in CHB patients who discontinue NA treatment.

153 all published studies including patients who discontinued NAs in virological remission (VR) and were

154 IDG discontinued natalizumab at once and initiated another d

155 roduction of porous Vycor glass was recently discontinued, new materials have been used lately as por

156 atients not treated beyond first progression discontinued nivolumab before or at RECIST-defined progr

157 outcomes seemed similar between patients who discontinued nivolumab plus ipilimumab treatment because

158 patients not treated beyond progression, who discontinued nivolumab therapy before or at progression

159 promising drug for those patients who shall discontinue NTZ.

160 All other antidiabetic drugs were discontinued on admission.

161 ft function requiring hemodialysis which was discontinued on postoperative days 18 and 39 for cases 1

162 nts completed the 48 weeks of treatment; two discontinued (one withdrew consent at week 8, one was lo

163 a; of the 33 patients whose antibiotics were discontinued, only two subsequently showed signs of lung

164 No patient discontinued or interrupted therapy due to adverse event

165 e who continued statin therapy and those who discontinued (OR, 0.98; 95% CI, 0.79-1.22).

166 or emergency department visits; reducing or discontinuing other asthma medications; and improving qu

167 ermine when surveillance can be decreased or discontinued; our study did not identify any BE or dyspl

168 ], or 6 mg per day); previous medication was discontinued over 2 weeks.

169 nts with CR and 89.9% in the 67 patients who discontinued pembrolizumab after CR for observation.

170 continued ipilimumab for one event and later discontinued pembrolizumab for another.

171 nts discontinued ipilimumab only and 14 (9%) discontinued pembrolizumab only because of treatment-rel

172 experienced virological breakthrough and one discontinued prematurely after the first day of treatmen

173 Ten participants withdrew consent or discontinued prematurely, 6 owing to adverse events attr

174 ggests that neuromuscular-blocking agents be discontinued prior to the clinical determination of brai

175 We discontinued randomisation at interim review when the fu

176 tinuation, and during retreatment, 1 patient discontinued ribavirin because of pruritus.

177 en in 129 (54%) of 237 patients, and 14 (6%) discontinued riociguat therapy because of adverse events

178 aseline hallucinations, 13 of 17 (76.5%) who discontinued risperidone relapsed, compared with 10 of 2

179 Discontinuing routine processing of screening urine cult

180 Furthermore, more than 50% of patients discontinue ruxolitinib treatment after 3-5 years.

181 dian follow-up of 79 months, 86 patients had discontinued ruxolitinib (30 of whom died while on thera

182 adverse event of mild headache and 3 (2.8%) discontinued scalp cooling due to feeling cold.

183 severe adverse events (nine, six, three); 12 discontinued (six, five, one); 24 had serious adverse ev

184 None of the patients discontinued sofosbuvir-velpatasvir-voxilaprevir therapy

185 ative sorafenib cost and were less likely to discontinue sorafenib because of gastrointestinal advers

186 y dermatologic reactions, and seven patients discontinued sorafenib after achieving complete response

187 osts, and a trend toward a decreased rate of discontinuing sorafenib because of adverse events.

188 as observed among those who continued versus discontinued statin therapy, suggesting the potential fo

189 n hospital discharge, 15.4% of beneficiaries discontinued statins.

190 ne patients were more likely than placebo to discontinue study drug by month 6 (20.4% versus 14.1%, P

191 37 (84%) patients had discontinued study drug as a result of progressive disea

192 Six patients were not assessable: three discontinued study drug because of a non-treatment-relat

193 and 137 (11%) patients in the placebo group discontinued study drug because of an adverse event (p=0

194 One participant with GT2 infection discontinued study medication after a single dose of gra

195 inally, there was no indication that mothers discontinued suckling because of a progressive rise in t

196 xhibited long-term benzodiazepine use (64.0% discontinued taking benzodiazepines after the initial fi

197 Treatment was discontinued temporarily for a median of 5 (range, 2-33)

198 e stopped early after the sponsor elected to discontinue the development of bococizumab owing in part

199 No patient permanently discontinued the active drug.

200 A total of 2.9% of patients discontinued the assigned regimen owing to adverse event

201 61% of patients (21/44), but only 1 patient discontinued the medication because of intolerance.

202 More patients receiving placebo discontinued the study because of adverse events (47.1%)

203 oseltamivir (n=205) twice a day; 11 patients discontinued the study before receiving any study treatm

204 ast one dose of study drug, who died, or who discontinued the study before the end of treatment for r

205 of run-in completion; 2079 (19.8%) subjects discontinued the study during the run-in period, includi

206 atients reported side-effects (three of whom discontinued the study): ear discomfort (n=6; three in t

207 32 (26%) patients in the tight control group discontinued the study, mostly because of adverse events

208 Twenty-seven patients discontinued the study, mostly because of gastrointestin

209 high-dose group, and 1 in the placebo group discontinued the trial regimen because of adverse events

210 Four patients discontinued the trial treatment prematurely because of

211 s making the possible diagnosis, altering or discontinuing the statin treatment, and using alternativ

212 ith a severe illness that might lead to them discontinuing the trial and those who had surgical revas

213 ART) randomized to continue (the CTX arm) or discontinue (the STOP-CTX arm) were examined for malaria

214 esolved in most patients when bortezomib was discontinued, the temporal relationship between initial

215 ge this disorder by lowering the dose of, or discontinuing, the causative drug.

216 erwent a protocol-defined mandatory taper to discontinue their oral corticosteroids.

217 Eligible patients were drug-naive or discontinued their antihypertensive medications.

218 (68%) and 168 (88%) patients, respectively, discontinued their assigned treatment before study end,

219 the end of the study, including patients who discontinued their assigned treatment.

220 Only 0 and 3 patients, respectively, discontinued their IOP-lowering medication.

221 ped early, and 9% were lost to follow-up; 9% discontinued their regimen early.

222 ew early, and 4% were lost to follow-up; 19% discontinued their regimen prematurely.

223 adherence, and 3705 (12.4%) and 4648 (18.8%) discontinued their statin, respectively.

224 le taking antiepileptic drugs might consider discontinuing their medication, with the possibility of

225 s on health, and some people have difficulty discontinuing their use of the drug.

226 nts receiving etanercept were more likely to discontinue therapy (hazard ratio = 1.87, 95% confidence

227 ast two treatments beyond confirmed CR could discontinue therapy.

228 d who either had a post-baseline scan or who discontinued therapy because of clinical disease progres

229 or patients without a post-baseline scan who discontinued therapy because of disease progression or a

230 C4 switched taxane, and 13 patients (21.3%) discontinued therapy before or at C4.

231 More patients in the experimental arm discontinued therapy due to adverse events (13 vs 7 pati

232 Overall, 18 (22%) of 83 patients discontinued therapy due to treatment-related toxicity.

233 needed in 2 patients and 2 others completely discontinued therapy for adverse events.

234 These results indicate that most people discontinuing therapy release a diverse population of vi

235 low some patients to maintain response after discontinuing therapy, a strategy that warrants further

236 Discontinuing thienopyridine after either 12 or 30 month

237 reports of myopic rebound after treatment is discontinued, this seems to be minimized by using low do

238 those who present in chronic phase (CP) can discontinue TKI treatment and maintain a therapy-free re

239 LSC are needed to enhance the possibility of discontinuing TKI treatment.

240 atment data when on-study treatment had been discontinued to understand disease behaviour during trea

241 0.06-0.42), and among all patients that had discontinued topical calcineurin inhibitors, those with

242 de 3 to 4 adverse events were more likely to discontinue treatment (31% v 12% for everolimus).

243 ESKD starting dialysis in sub-Saharan Africa discontinue treatment and die.

244 Two of the three patients had to discontinue treatment prematurely and the third required

245 After exclusion of patients who discontinued treatment (n=1 in the PENFS group; n=7 in t

246 mg of ticagrelor, and placebo, respectively, discontinued treatment (P < .001).

247 combined with ipilimumab in clinical trials discontinued treatment because of adverse events (AEs).

248 No patient discontinued treatment because of adverse events or viro

249 both trials, the proportion of patients who discontinued treatment because of adverse events was low

250 he semaglutide group, although more patients discontinued treatment because of adverse events, mainly

251 aminotransferase and no patients prematurely discontinued treatment because of adverse events.

252 One patient (<1%) discontinued treatment because of adverse events.

253 No patients discontinued treatment because of adverse events.

254 ree survival was 8.4 months for patients who discontinued treatment because of AEs during the inducti

255 of nivolumab plus ipilimumab in patients who discontinued treatment because of AEs.

256 One patient permanently discontinued treatment because of an adverse event (sync

257 No patients discontinued treatment because of an adverse event.

258 the total population, and 45 (11%) patients discontinued treatment because of an adverse event.

259 No patients discontinued treatment because of an adverse event.

260 Five (3%) patients discontinued treatment because of an adverse event.

261 One patient in the anakinra group discontinued treatment because of an adverse event.

262 dverse events (AEs) occurred, and no patient discontinued treatment because of an adverse event.

263 similar between groups, and few participants discontinued treatment due to adverse events (5 [2%] of

264 Two discontinued treatment due to adverse events and 2 had s

265 ated adverse events (mostly grade 1-2); none discontinued treatment due to adverse events.

266 Three patients (1%) discontinued treatment due to adverse events.

267 No patients discontinued treatment due to an adverse event.

268 e primarily mild or moderate, and no patient discontinued treatment due to an AE.

269 One patient discontinued treatment due to liver cancer and died 22 d

270 Two cirrhotic patients relapsed and 2 discontinued treatment due to serious adverse events.

271 rs), 3 completed 3 cycles of treatment and 2 discontinued treatment early owing to disease progressio

272 patients did not complete the study, and 11 discontinued treatment early.

273 One patient discontinued treatment on day 45 due to adverse events.

274 both trials, the percentage of patients who discontinued treatment owing to adverse events was 1% or

275 One patient treated with fluconazole discontinued treatment owing to malaise, headache, and m

276 participants assigned to 0.5 mg semaglutide discontinued treatment prematurely, compared with 55 (15

277 However, more patients prematurely discontinued treatment with ticagrelor than with placebo

278 In this phase, 46 (96%) of 48 patients discontinued treatment, 42 (88%) due to disease progress

279 hs (IQR 6.7-15.2) and 147 (60%) patients had discontinued treatment, 98 (40%) as a result of disease

280 Seven patients (4%) discontinued treatment, and one died of treatment-relate

281 ) in the ipilimumab every-6-weeks cohort had discontinued treatment.

282 e event; of these patients, nine permanently discontinued treatment.

283 boratory abnormalities were rare; no patient discontinued treatment.

284 emaglutide, and 14 (11%) assigned to placebo discontinued treatment; the main reason for discontinuat

285 4 infections, and three versus zero patients discontinuing treatment because of unacceptable toxicity

286 ants who completed the FREEDOM trial without discontinuing treatment or missing more than one dose of

287 Many women discontinued tube feeding because of discomfort, suggest

288 Four patients discontinued (two because of drug-related adverse events

289 Discontinuing unhealthy behaviors, such as overeating or

290 itive deficits, particularly in subjects who discontinue use in adulthood, are mixed.

291 eater effects of continued cannabis use than discontinued use on relapse (dCC-NC=0.36 vs dDC-NC=0.02,

292 dCC-NC=0.36, 95% CI 0.22-0.50, p<0.0001) and discontinued users (dCC-DC=0.28, 0.12-0.44, p=0.0005), a

293 Of these, 360 (30.6%) discontinued warfarin treatment during the first year.

294 a CHA2DS2-VASc score of 2 or more, patients discontinuing warfarin treatment had a higher rate of is

295 d to CBT who had antidepressants tapered and discontinued were significantly less likely to experienc

296 ntinued OIT for 8 weeks, after which OIT was discontinued with rechallenge at month 32 to assess sust

297 Six women discontinued with the allocated treatment because of the

298 All inotropes and vasopressors were discontinued within 12 hours of pacemaker optimization o

299 Enteral tube feeding was discontinued within 7 d of placement in the remaining wo

300 Although 17% of participants discontinued X-82 owing to AEs, those who completed the